Artiva Biotherapeutics halts lead cell therapy, cuts ~94% of workforce, explores strategic alternatives
Artiva Biotherapeutics (NASDAQ:ARTV) is halting further clinical development of its lead cell therapy candidate and slashing roughly 94% of its workforce, per Benzinga. The company is evaluating strategic alternatives, which could include liquidation. The crisis follows patient deaths tied to the program.
Source:
benzinga.com: https://www.benzinga.com/markets/biotech/26/10/62631388/artiva-biotherapeutics-plunges-into-crisis-over-patient-deaths-and-possible-liquidation
Not financial advice. For informational and educational purposes only.
$BA stock call: Not yet, buy zone $137 to $156
$BA: not yet. I'd buy around $137 to $156. Down 10% today to a new 52-week low near $169 22% below its 200-day after Q3 I think it gets cheaper because the 737 ramp slipped to 2027 and cash flow slips with it.
FCC approves Amazon Leo's $11.57B acquisition of Globalstar
The FCC has approved Amazon's $11.57 billion acquisition of Globalstar, per Reuters. The decision clears…
$BA daily pick: sell Dec 18 $160 put (buy-side) after the Q3 selloff
$BA: I'm selling the Dec 18 $160 put on @Boeing after today's 10% drop and getting paid to wait. As of midday ($169.99): Lowest since April 2025 and 22% below the 200-day Credit $3.55 for ~2.2% in 52 days (~16% annualized) Breakeven $156.45, about 8% below today Record $745B backlog
Afternoon update
$NBIS rose 10.78% Tuesday as AI-infrastructure names rallied after Anthropic's preliminary IPO filing, while refiners took the other side of the…
$NBIS rose 10.78% Tuesday as AI-infrastructure names rallied after Anthropic's preliminary IPO filing, while refiners took the other side of the tape. Nebius (+10.78%, $40.8B) and Astera Labs (+9.86%, $49.3B) advanced on Anthropic's preliminary IPO filing and a lender…